G. Caramori (Messina, Italy), T. Maes (Ghent, Belgium)
Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation
T. Greulich (Marburg, Germany)
|  |
Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients.
E. Khokhlovich (Cambridge, United States of America)
|   |
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY
M. Scuri (PARMA, PR, Italy)
| |
Late Breaking Abstract - Lung deflation with Indacaterol/Glycopyrronium improves cardiac function in COPD patients: The CLAIM Study
J. Hohlfeld (Hannover, Germany)
| |
Late Breaking Abstract - The first direct comparison between BAL-fluid and the PExA methodology in healthy individuals.
A. Behndig (Umeå, Sweden)
| |
Late Breaking Abstract - Activation of Notch1 signalling promotes Bone Marrow-derived Mesenchymal Stem Cells proliferation, migration and survival in COPD microenvironment via PI3K/Akt
Y. Cheng (China)
| |
Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies
J. Fitzgerald (Vancouver, BC, Canada)
| |
Late Breaking Abstract - Reslizumab vs benralizumab in patients with inadequately controlled asthma: a Bayesian network meta-analysis
T. Casale (Tampa, United States of America)
| |